Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novozymes Will Close Hyaluronic Acid Plant
January 14, 2008
| A version of this story appeared in
Volume 86, Issue 2
Novozymes is closing a plant in Shandong province, China, that produces hyaluronic acid via Streptococcus bacteria fermentation. The plant employs 132 people. Novozymes bought the plant in 2006 to complement its existing Bacillus-based production but subsequently encountered price erosion in the dietary supplement market and a low-growth outlook in the technical market. Novozymes says it will continue to develop its Bacillus products for high-end applications such as eye drops, drug delivery, and tissue engineering.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X